121 related articles for article (PubMed ID: 25979323)
1. Enhanced delivery of liposomes to lung tumor through targeting interleukin-4 receptor on both tumor cells and tumor endothelial cells.
Chi L; Na MH; Jung HK; Vadevoo SM; Kim CW; Padmanaban G; Park TI; Park JY; Hwang I; Park KU; Liang F; Lu M; Park J; Kim IS; Lee BH
J Control Release; 2015 Jul; 209():327-36. PubMed ID: 25979323
[TBL] [Abstract][Full Text] [Related]
2. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor.
He X; Na MH; Kim JS; Lee GY; Park JY; Hoffman AS; Nam JO; Han SE; Sim GY; Oh YK; Kim IS; Lee BH
Mol Pharm; 2011 Apr; 8(2):430-8. PubMed ID: 21222482
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Tumor Growth against Chemoresistant Cholangiocarcinoma by a Proapoptotic Peptide Targeting Interleukin-4 Receptor.
Permpoon U; Khan F; Vadevoo SMP; Gurung S; Gunassekaran GR; Kim MJ; Kim SH; Thuwajit P; Lee B
Mol Pharm; 2020 Nov; 17(11):4077-4088. PubMed ID: 32881535
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-4 receptor-targeted delivery of Bcl-xL siRNA sensitizes tumors to chemotherapy and inhibits tumor growth.
Guruprasath P; Kim J; Gunassekaran GR; Chi L; Kim S; Park RW; Kim SH; Baek MC; Bae SM; Kim SY; Kim DK; Park IK; Kim WJ; Lee B
Biomaterials; 2017 Oct; 142():101-111. PubMed ID: 28732245
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy.
Kawakami M; Kawakami K; Stepensky VA; Maki RA; Robin H; Muller W; Husain SR; Puri RK
Clin Cancer Res; 2002 Nov; 8(11):3503-11. PubMed ID: 12429641
[TBL] [Abstract][Full Text] [Related]
6. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.
Takara K; Hatakeyama H; Kibria G; Ohga N; Hida K; Harashima H
J Control Release; 2012 Aug; 162(1):225-32. PubMed ID: 22728515
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer.
Yang CY; Liu HW; Tsai YC; Tseng JY; Liang SC; Chen CY; Lian WN; Wei MC; Lu M; Lu RH; Lin CH; Jiang JK
Cancer Biol Ther; 2015; 16(11):1641-50. PubMed ID: 26436767
[TBL] [Abstract][Full Text] [Related]
8. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
[TBL] [Abstract][Full Text] [Related]
9. Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells.
Niiya M; Niiya K; Kiguchi T; Shibakura M; Asaumi N; Shinagawa K; Ishimaru F; Kiura K; Ikeda K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2003 Nov; 52(5):391-8. PubMed ID: 12908082
[TBL] [Abstract][Full Text] [Related]
10. Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78.
Katanasaka Y; Ishii T; Asai T; Naitou H; Maeda N; Koizumi F; Miyagawa S; Ohashi N; Oku N
Int J Cancer; 2010 Dec; 127(11):2685-98. PubMed ID: 20178102
[TBL] [Abstract][Full Text] [Related]
11. Non-genetic engineering of cytotoxic T cells to target IL-4 receptor enhances tumor homing and therapeutic efficacy against melanoma.
Gunassekaran GR; Hong CM; Vadevoo SMP; Chi L; Guruprasath P; Ahn BC; Kim HJ; Kang TH; Lee B
Biomaterials; 2018 Mar; 159():161-173. PubMed ID: 29329051
[TBL] [Abstract][Full Text] [Related]
12. Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors.
Lowery A; Onishko H; Hallahan DE; Han Z
J Control Release; 2011 Feb; 150(1):117-24. PubMed ID: 21075152
[TBL] [Abstract][Full Text] [Related]
13. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4.
Obiri NI; Hillman GG; Haas GP; Sud S; Puri RK
J Clin Invest; 1993 Jan; 91(1):88-93. PubMed ID: 8423237
[TBL] [Abstract][Full Text] [Related]
14. Antagonist G-mediated targeting and cytotoxicity of liposomal doxorubicin in NCI-H82 variant small cell lung cancer.
Moreira JN; Gaspar R
Braz J Med Biol Res; 2004 Aug; 37(8):1185-92. PubMed ID: 15273819
[TBL] [Abstract][Full Text] [Related]
15. Preparation and antitumor activity of bFGF-mediated active targeting doxorubicin microbubbles.
Wu Y; Lu CT; Li WF; Sun CZ; Yang W; Zhang Y; Su ZX; Zhang Y; Fu HX; Huang PT; Lv HF; Dai DD; Li X; Lin GY; Luo SM; Zhao YZ
Drug Dev Ind Pharm; 2013 Nov; 39(11):1712-9. PubMed ID: 23062067
[TBL] [Abstract][Full Text] [Related]
16. In situ dose amplification by apoptosis-targeted drug delivery.
Wang K; Na MH; Hoffman AS; Shim G; Han SE; Oh YK; Kwon IC; Kim IS; Lee BH
J Control Release; 2011 Sep; 154(3):214-7. PubMed ID: 21763738
[TBL] [Abstract][Full Text] [Related]
17. A specific peptide ligand-modified lipid nanoparticle carrier for the inhibition of tumor metastasis growth.
Wang Z; Yu Y; Dai W; Cui J; Wu H; Yuan L; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
Biomaterials; 2013 Jan; 34(3):756-64. PubMed ID: 23117217
[TBL] [Abstract][Full Text] [Related]
18. Human epidermal growth factor receptor-2 antibodies enhance the specificity and anticancer activity of light-sensitive doxorubicin-labeled liposomes.
Li Q; Tang Q; Zhang P; Wang Z; Zhao T; Zhou J; Li H; Ding Q; Li W; Hu F; Du Y; Yuan H; Chen S; Gao J; Zhan J; You J
Biomaterials; 2015 Jul; 57():1-11. PubMed ID: 25956192
[TBL] [Abstract][Full Text] [Related]
19. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer.
Moura V; Lacerda M; Figueiredo P; Corvo ML; Cruz ME; Soares R; de Lima MC; Simões S; Moreira JN
Breast Cancer Res Treat; 2012 May; 133(1):61-73. PubMed ID: 21805188
[TBL] [Abstract][Full Text] [Related]
20. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
